Abstract: The invention relates to medicine and the chemical and pharmaceutical industry and to agent for treating diseases caused by angiogenesis regulation disorders, in particular to a method for treating oncological diseases of different genesis by inducing angiogenesis inhibition which is secondary to the direct antitumoral, anti-reccurant and anti-metastatic action as well as by the associated activation of the apoptosis endogenous system. The invention uses a novel peroral medicinal form ‘Abisilin’, comprising ingredients relating to the class of natural terpene compounds (isoprenoids), produced from coniferous threes of a Pinaceue family, which medicinal form contains: sesquiterpenoids (3-6%), neutral diterpenoids (11-15%), diterpene acids (22-28%), triterpene acids (8-16%), unsaturated and saturated fatty acids (0.1-0.3%), phenolic compounds (0.1-0.2%), monoterpenoids being the rest, wherein the bornyl acetate content is equal to not less that 10.0% of the total terpene composition.